The investigational therapy, ifinatamab deruxtecan, is a potential first-in-class B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed with Merck
New Yamuna Vihar facility to train 40 students annually through diploma-led, hands-on renal care education
Exclusive distribution pact with Amcor broadens access to Parafilm M sealing solutions for laboratories, horticulture and industrial users
Strong limited rollout adoption across major hospital networks positions company for accelerated scale-up in interventional radiology
Three-year CSR partnership to scale community-led mental healthcare access across Chhindwara district
CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing
Move amid evidence of widespread reporting gaps
AI-enabled women’s digital clinic brings in-person consultations to complement app-led care after serving over 400,000 women across India
Subscribe To Our Newsletter & Stay Updated